Ambulatory and short-burst oxygen for interstitial lung disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Sharp, Charles ^a   Adamali, Huzaifa ^b   Millar, Ann B ^c  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b NORTH BRISTOL NHS TRUST   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBULATORY OXYGEN THERAPY; ARTICLE; CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; DISEASE EXACERBATION; DYSPNEA; EXERCISE; HOSPITALIZATION; HUMAN; INTERSTITIAL LUNG DISEASE; OUTCOME ASSESSMENT; OXYGEN THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SHORT BURST OXYGEN THERAPY; SURVIVAL RATE; SYSTEMATIC REVIEW;

EID: 84977609478     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011716     Document Type: Article

References (15)

1. British Thoracic Society (BTS) Working Group on Home Oxygen Services. Clinical component for the home oxygen service in England and Wales. www.brit-thoracic.org.uk/document-library/clinical-information/oxygen/home-oxygen-guideline-%28adults%29/bts-home-oxygen-in-adults-clinical-component/ January 2006 (accessed 20 January 2015).
2. Hardinge M, Annandale J, Bourne S, Cooper B, Evans A, Freeman D, et al. British Thoracic Society Home Oxygen Guideline Development Group, on behalf of the British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for home oxygen use in adults. Thorax 2015;70:i1-i43.
3. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
4. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine 2014;370(22):2083-92.
5. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. American Journal of Respiratory and Critical Care Medicine 2003;168(9):1084-90.
6. McDonald CF, Blyth CM, Lazarus MD, Marschner I, Barter CE. Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxaemia. American Journal of Respiratory and Critical Care Medicine 1995;152(5 Pt 1):1616-9.
7. Nandi K, Smith AA, Crawford A, MacRae KD, Garrod R, See WA, et al. Oxygen supplementation before or after submaximal exercise in patients with chronic obstructive pulmonary disease. Thorax 2003;58(8):670-3.
8. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011;66(6):462-7.
9. National Institute for Health and Care Excellence. Idiopathic pulmonary fibrosis: the diagnosis and management of suspected idiopathic pulmonary fibrosis. www.nice.org.uk/guidance/cg163 June 2013 (accessed 20 January 2015).
10. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
11. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. The New England Journal of Medicine 2014;370(22):2071-82.
12. Roberts CM. Short burst oxygen therapy for relief of breathlessness in COPD. Thorax 2004;59(8):638-40.
13. Ryerson CJ, Donesky D, Pantilat SZ, Collard HR. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. Journal of Pain and Symptom Management 2012;43(4):771-82.
14. Stevenson NJ, Calverley PM. Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease. Thorax 2004;59(8):668-72.
15. Visca D, Montgomery A, .de Lauretis A, Sestini P, Soteriou H, Maher TM, et al. Ambulatory oxygen in interstitial lung disease. The European Respiratory Journal 2011;38(4):987-90.